Takeda's $13.6 Bil. Nycomed Buy Meets Multiple Strategic, Financial Imperatives
Takeda Pharmaceuticals Co. Ltd.'s €9.6 billion ($13.6 billion) purchase of privately held Nycomed AS, confirmed May 19 after a week of speculation, satisfies a number of strategic and financial imperatives for Japan's largest drug maker, as it faces generic competition to best-selling diabetes drug Actos (pioglitazone) from 2012 and seeks to expand its footprint beyond Japan and the U.S.
You may also be interested in...
Deal Watch: Valeant’s Financial/Commercial Strength Offers A New Chance For Provenge
AstraZeneca buys out respiratory franchise from Actavis, which it had gained a year prior with its purchase of Forest. Mylan announced two deals Feb. 2, collaborating in COPD with Theravance and buying women’s health products from India’s Famy Care.
Deals Of The Week: Big Pharmas Hoard Cash, But Aren’t Buying Yet In 2013
DOTW digs into a Moody’s report detailing which companies’ balance sheets have the most cash, even if the pharmas that made the cut haven’t been putting their purchasing power to work. In addition, details on Valeant’s latest dermatology acquisition, Merck’s deal with Cerecor for a portfolio of COMT assets, Janssen’s European cancer research tie-up, and an NPS/Takeda deal for orphan drugs.
NPS Moves Toward Status As Global Orphan Drug Firm With Takeda Agreement
In a deal that moves a $50 million equity stake to Takeda, NPS reacquires ex-U.S. rights to teduglutide and PTH 1-84, enabling the New Jersey firm to position itself as a worldwide orphan drug specialist. Takeda also can earn a $30 million one-time, sales-dependent milestone under the deal.